CN1985821A - 小花棘豆总生物碱和氮己环酮衍生物的制药用途 - Google Patents
小花棘豆总生物碱和氮己环酮衍生物的制药用途 Download PDFInfo
- Publication number
- CN1985821A CN1985821A CN 200510131942 CN200510131942A CN1985821A CN 1985821 A CN1985821 A CN 1985821A CN 200510131942 CN200510131942 CN 200510131942 CN 200510131942 A CN200510131942 A CN 200510131942A CN 1985821 A CN1985821 A CN 1985821A
- Authority
- CN
- China
- Prior art keywords
- compd
- total alkaloids
- arrhythmia
- tetramethyl
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 44
- 241000293302 Astragalus mollissimus Species 0.000 title claims description 12
- 150000003797 alkaloid derivatives Chemical class 0.000 title abstract description 6
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 16
- 230000006793 arrhythmia Effects 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 206010020772 Hypertension Diseases 0.000 claims abstract description 11
- -1 inorganic acid salt Chemical class 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 241000220099 Oxytropis glabra Species 0.000 claims abstract description 5
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 3
- 230000001631 hypertensive effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000000213 tachycardiac effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000147945 Oxytropis kansuensis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- CGFYHILWFSGVJS-UHFFFAOYSA-N silicic acid;trioxotungsten Chemical compound O[Si](O)(O)O.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 CGFYHILWFSGVJS-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品名称 | 浓度(mg/ml) | 起效时间(分钟) | 松弛时间(小时) |
异丙肾上腺素化合物A总生物碱 | 5×10-51×10-45×10-3 | 1635 | 0.387 |
样品名称 | 浓度(mg/ml) | 起效时间(分钟) | 收缩力 |
异丙肾上腺素总生物碱化合物A | 1.2×10-65×10-31×10-4 | 1653 | 10.40.2 |
组别n=10 | 基础心律X±SD | ||
对照病理心得安总生物碱化合物A | 造模前349.7±SD12.4279.4±SD36.2305.1±SD22.6329.1±SD42.5318.1±SD42.6 | 造模后355.7±SD13.4401.8±SD13.3332.8±SD25.4354.2±SD23.7341.6±SD25.4 | 变化量X±SD6±SD21.060.7±SD23.427.1±SD21.2**26.9±SD18.5**23.5±SD34.6** |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510131942A CN100594026C (zh) | 2005-12-22 | 2005-12-22 | 小花棘豆总生物碱和氮己环酮衍生物的制药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510131942A CN100594026C (zh) | 2005-12-22 | 2005-12-22 | 小花棘豆总生物碱和氮己环酮衍生物的制药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1985821A true CN1985821A (zh) | 2007-06-27 |
CN100594026C CN100594026C (zh) | 2010-03-17 |
Family
ID=38182848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510131942A Expired - Fee Related CN100594026C (zh) | 2005-12-22 | 2005-12-22 | 小花棘豆总生物碱和氮己环酮衍生物的制药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100594026C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103202872A (zh) * | 2013-04-08 | 2013-07-17 | 塔里木大学 | 一种小花棘豆黄酮的制备方法及其应用 |
-
2005
- 2005-12-22 CN CN200510131942A patent/CN100594026C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103202872A (zh) * | 2013-04-08 | 2013-07-17 | 塔里木大学 | 一种小花棘豆黄酮的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100594026C (zh) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69223157T2 (de) | Sauerstoff-substituierte derivate von nucleophil-stickstoffoxid-addukten und ihre verwendung als stickstoffoxid-donor-prodrugs | |
DE69909209T2 (de) | Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung | |
Mitchell et al. | The metabolism of [14C] cimetidine in man | |
CN103735500A (zh) | 盐酸他喷他多注射液及其制备方法 | |
CN108926564A (zh) | 一种非去极化肌松剂组合物及其制备方法和用途 | |
CN100594026C (zh) | 小花棘豆总生物碱和氮己环酮衍生物的制药用途 | |
DE102014008685A1 (de) | Freisetzungssystem für therapeutisches Gas | |
See | Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride | |
BR112019018966A2 (pt) | analógicos da deutetrabenazina, sua preparação e uso | |
CN107141284B (zh) | 黄连碱类衍生物、其制备方法、药物组合物及抗肿瘤用途 | |
JP4566128B2 (ja) | イリノテカン塩酸塩の結晶多形の製造方法 | |
CN101230035B (zh) | 门冬氨酸氨氯地平系列盐及其制备方法和其组合物、制剂以及片剂 | |
CN100534427C (zh) | 银杏叶提取物及其制剂 | |
CN101331112B (zh) | 一种联苯乙酸盐及其制备方法与应用 | |
CN102229564A (zh) | 4-(7-氯-4氨基喹啉)-5、6、7、8-四氢-α-萘酚衍生物及其制备方法与应用 | |
Abdul-Ghani et al. | Hypoglycemic effect of copper (II) acetate imidazole complexes | |
DE2034640C3 (de) | l-p-(7-Trifluormethyl-4-chinolyl) -amino-benzoyl-piperazine, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Bluthochdruck | |
FI63575C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara okahydro-indolo(2,3-a)kinolizinderivat | |
BRPI0720292A2 (pt) | Extrato especial e uso do mesmo para inibição da degradação de monofosfato de guanosina cíclica (cgmp) | |
CN106420850B (zh) | 银杏叶组合物及其在制备舒血宁注射液中的应用 | |
CN100494190C (zh) | 一种含邻萘醌结构的化合物及其应用 | |
CN104876942B (zh) | 单硝酸异山梨酯半水化合物 | |
CN109336801A (zh) | 一类度骨化醇衍生物及其制备方法 | |
US20040229836A1 (en) | Compounds having selective hydrolytic potentials | |
CN105198810A (zh) | 2-苄基-1-异喹啉酮类化合物及其合成方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhao Hong Document name: Written notice of preliminary examination of application for patent for invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180213 Address after: 100165 Beijing city Fengtai District xiaoyueyuan Wu Li No. 4 Building 1402 room Patentee after: Tuolin Medicine Sci-Tech Co., Ltd., Beijing Address before: Hebei city of Qinhuangdao Province Qin District 066000 12 Building 1 unit 10 Patentee before: Yang Xing |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100317 Termination date: 20181222 |